Effects of papaverine on hepatic, splenic and renal hemodynamics in patients after liver transplantation: a randomized controlled trial

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2400087258

Enrollment

Unknown

Registered

2024-07-23

Start date

2023-08-27

Completion date

Unknown

Last updated

2024-07-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Liver transplantation

Interventions

Papaverine group:Papaverine

Crotrol group:phloroglucinol

Eligibility

Sex/Gender

All

Age

18 Years to 65 Years

Inclusion criteria

Inclusion criteria: (1) 18-65 years old (no gender restriction); (2) Patients with liver failure who were to undergo liver transplantation had MELD score < 35 before surgery; (3) Abdominal spasm pain after operation.

Exclusion criteria

Exclusion criteria: 1) Postoperative MAP=60mmHg; (2) The primary donor liver is not functional; (3) Patients with primary kidney disease; (4) After splenectomy; (5) Patients with contraindications to papaverine use, such as complete atrioventricular block, Parkinson's disease, or hemorrhagic cerebral infarction.

Design outcomes

Secondary

Measure	Time frame
Portal vein blood flow;Mean splenic artery flow rate;Splenic venous blood flow;Splenic artery resistance index;Mean renal artery flow rate;Renal artery resistance index;Renal venous blood flow;	—

Primary

Measure	Time frame
Mean hepatic artery flow rate;Hepatic arterial resistance index;	—

Countries

China

Contacts

Public ContactBo Xu

Huashan Hospital Affiliated to Fudan University

xubo-mazui@163.com+86 172 6939 9353

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026